TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3516953
Drug: MFD (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFD (3 X 1.6 Gy/day for 10 days, 3 weeks rest, followed by a boost to 67.2 or 72 Gy) + Misonidazole (1 g/m2 every irradiation day, total 12 to 14 g/m2)
Study: 26987980
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day oral diclofenac
Study: 26987980
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg methylprednisolone injection
Study: 26987980
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (diclofenac + methylprednisolone)
Study: 17460970
Drug: Trimethasidine MB
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethasidine MB (70 mg daily)
Study: 17460970
Drug: 3‐TMHP (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐TMHP (1000 mg daily)
Study: 17460970
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic therapy with ACE inhibitors, beta-blockers, and diuretics)
Study: 9807986
Drug: Irinotecan 300-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 300-350 mg/m2 infused once every 3 weeks
Study: 9807986
Drug: Fluorouracil by
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil by continuous infusion
Study: 100029
Drug: Streptomycin, isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin, isoniazid, and rifampin given daily for 6 months
Study: 100029
Drug: Streptomycin, isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin, isoniazid, rifampin, and pyrazinamide given daily for 2 months, followed by twice-weekly administration of streptomycin, isoniazid, and pyrazinamide
Study: 100029
Drug: Streptomycin, isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin, isoniazid, rifampin, and pyrazinamide given 3 times per week for 4 months, followed by streptomycin, isoniazid, and pyrazinamide administered twice per week
Study: 26454228
Drug: Preconceptional micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconceptional micronutrient supplements
Study: 23506690
Drug: Traditional herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional herbal medicine (THM) regimen including Cinobufacini injection and Jiedu Granule
Study: 11815577
Drug: Clarithromycin MR
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin MR 500 mg once daily for 5 days
Study: 11815577
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 590 mg three times daily for 10 days
Study: 24367678
Drug: Efavirenz-based antiretroviral
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz-based antiretroviral therapy
Study: 23381882
Drug: Ritonavir 20
Normalized name: ritonavir 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 20 mg (phase 2)
Study: 23381882
Drug: Ritonavir 100
Normalized name: ritonavir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 100 mg (phase 3)
Study: 17309962
Drug: Intermittent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sequential pneumatic compression (ISPC) device activated over the lower limbs 15 minutes after PPP was established for the remainder of surgery.
Study: 7978435
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms oral clonidine administered just before anesthesia
Study: 7978435
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms oral clonidine administered 1 h before anesthesia
Study: 7978435
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms oral clonidine administered 3 h before anesthesia
Study: 1104900
Drug: standard hormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard hormonal or other therapies
Study: 23406306
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling by phone, access to twice‐weekly exercise sessions, information on healthy eating and physical activity provided in pamphlets, evening meetings and an interactive website.
Study: 21726928
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (Group AGO)
Study: 21726928
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (Group ANTAG)
Study: 12851342
Drug: Hylan G‐F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G‐F 20 (Synvisc)
Study: 10383511
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose spearmint (500 mg)
Study: 10383511
Drug: Flavouring dose
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flavouring dose spearmint (0.5 mg)
Study: 8723601
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone (2 mg/kg in 15 min followed by 1 mg/kg in 2 h)
Study: 1685992
Drug: Urapidil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (40 mg bolus followed by an infusion of 18 mg.h‐1 for 2 h)
Study: 6809393
Drug: Almitrine at
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine at a dose of 0.5 mg h‐1 kg‐1 given intravenously over 2 h
Study: 25778317
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiotherapy combined with concurrent combination chemotherapy (cisplatin and 5‐fluorouracil)
Study: 22390068
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei DN - 114001 (109 cells daily for 3 months)
Study: 8097925
Drug: Epanolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol (200 mg)
Study: 8097925
Drug: Epanolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol (mean 300 mg/day for 10 months)
Study: 8097925
Drug: Epanolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol (300 mg/day)
Study: 8097925
Drug: Atenolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (150 mg/day)
Study: 22475362
Drug: Bleeding-avoidance strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleeding-avoidance strategies (BAS) including direct thrombin inhibitors and vascular closure devices
Study: 19821701
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with an 830-nm diode laser, 40 mW, 1.04 J per point, applied on days 1, 3, 5, and 7 post-surgery
Study: 15969244
Drug: Cimicifuga racemosa
Normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga racemosa (CR) 40 mg daily
Study: 15969244
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal estradiol (TTSE2) 25 microg every 7 days plus dihydrogesterone 10 mg/day for the last 12 days
Study: 14686229
Drug: Ganciclovir (oral)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir (oral)
Study: 14686229
Drug: CMV immune
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV immune globulin i.v. and oral acyclovir
Study: 10570746
Drug: Goat IgG
Normalized name: Goat milk
DrugBank: Goat milk (DB10542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goat IgG antiidiotype vaccine SCV 106 (n = 21)
Study: 8966142
Drug: None of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: None of these drugs
Study: 20495473
Drug: Conditioned placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioned placebo dose reduction condition (50% reduced dose/placebo)
Study: 20495473
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction only condition (RD)
Study: 20495473
Drug: No reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No reduction condition (full dose)
Study: 19086953
Drug: Intensive regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive regimen (80 mg bolus followed by 8 mg/h continuous infusion for 72 h)
Study: 19086953
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (40 mg bolus daily followed by saline infusion for 72 h)
Study: 12267108
Drug: Continuation rates
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation rates at 24 months: Cu7 (69), TCu-220C (73), ML Cu250 (74).
Study: 22336776
Drug: Nitrate 100
Normalized name: silver nitrate 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate 100 mg
Study: 22336776
Drug: Nitrate 200
Normalized name: silver nitrate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate 200 mg
Study: 22336776
Drug: Nitrate 400
Normalized name: silver nitrate 400 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate 400 mg
Study: 22336776
Drug: Nitrate 400
Normalized name: silver nitrate 400 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate 400 mg plus antibacterial toothpaste
Study: 22336776
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Nitrate (Control)
Study: 22336776
Drug: Nitrate doses
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate doses (100 mg, 200 mg, 400 mg)
Study: 20129511
Drug: Amantadine 4
Normalized name: amantadine 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 4 mg/kg/day for 7 days followed by 6 mg/kg/day for 14 days
Study: 17509511
Drug: Topical 0.02%
Normalized name: tretinoin topical 0.02% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.02% mitomycin C (MMC) applied for 15 seconds during PRK
Study: 16284692
Drug: Prophylactic parenteral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic parenteral nutrition (PN)
Study: 16284692
Drug: PN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN with 0.5 g glutamine/kg as L‐Ala‐L‐Gln
Study: 7778387
Drug: Glycine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (daily dose 1-2 grams)
Study: 2316281
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 0.03-3.0 micrograms antigen per dose
Study: 37045
Drug: Azatadine maleate
Normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azatadine maleate 2 mg
Study: 37045
Drug: Azatadine maleate
Normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azatadine maleate 4 mg
Study: 37045
Drug: Azatadine maleate
Normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azatadine maleate 8 mg
Study: 31190327
Drug: ENR-IV (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENR-IV (10 mg/kg, IV)
Study: 31190327
Drug: ENR-IM (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENR-IM (10 mg/kg, IM)
Study: 31190327
Drug: DNX-IV (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNX-IV (8 mg/kg, IV)
Study: 31190327
Drug: DNX-IM (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNX-IM (8 mg/kg, IM)
Study: 24148291
Drug: 5% methimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% methimazole ointment applied to the skin around the thyroid and an oral placebo
Study: 24148291
Drug: Methimazole tablets
Normalized name: Methimazole Tablets
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole tablets and placebo ointment
Study: 24148291
Drug: 5% methimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% methimazole ointment
Study: 24148291
Drug: Methimazole tablets
Normalized name: Methimazole Tablets
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole tablets
Study: 21798557
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of 1‐month depot leuprolide acetate (DL)
Study: 21798557
Drug: 11.25 mg
Normalized name: phentermine 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg of 3‐month depot leuprolide acetate (DL)
Study: 21798557
Drug: 22.5 mg
Normalized name: inositol 22.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg of 3‐month depot leuprolide acetate (DL)
Study: 16867922
Drug: Major depressive
Normalized name: Rejoyn Digital Therapeutic Software for Major Depressive Disorder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major depressive disorder with concurrent substance use disorder (SUD)
Study: 16867922
Drug: Major depressive
Normalized name: Rejoyn Digital Therapeutic Software for Major Depressive Disorder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major depressive disorder without concurrent substance use disorder (SUD)
Study: 10506597
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with doxorubicin 75 mg/m(2) every 2 weeks for three cycles followed by docetaxel 100 mg/m(2) every 2 weeks for three cycles
Study: 10506597
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with doxorubicin 56 mg/m(2) plus docetaxel 75 mg/m(2) every 3 weeks for four cycles
Study: 1671951
Drug: Paracetamol liquid
Normalized name: RP Scherer Paracetamol Liquid-Filled Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol liquid 10-15 mg/kg every 4 hours as needed for fever
Study: 28985094
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for first-time dislocation with operative osteochondral fracture requiring excision or repair
Study: 28985094
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for recurrent instability, favoring medial reconstruction
Study: 28300867
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg bid
Study: 24220913
Drug: CRP concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP concentrations ≥ 10.0 mg/L
Study: 23082602
Drug: Multi-level oral
Normalized name: Finafta Multi Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-level oral health intervention (home visits by lay health workers, enhancing oral health education and services at health centers, community mobilization)
Study: 10543733
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of body weight daily
Study: 10543733
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg daily
Study: 10543733
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg weekly
Study: 8559630
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (fourth dose)
Study: 8559630
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (booster)
Study: 2378546
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d of haloperidol
Study: 2378546
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of haloperidol
Study: 2378546
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d of haloperidol
Study: 31657804
Drug: 14 improvisational
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 improvisational music therapy sessions on a weekly basis (Group 1)
Study: 31657804
Drug: 7 improvisational
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 improvisational music therapy sessions alternated with 7 listening music therapy sessions on a weekly basis (Group 2)
Study: 26395174
Drug: PER/AML 8/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PER/AML 8/10 mg
Study: 20585834
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing algorithm for warfarin therapy
Study: 20585834
Drug: Mean warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean warfarin requirements ≤ 3 mg/day
Study: 20585834
Drug: Mean warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean warfarin requirements > 3 mg/day
Study: 17902000
Drug: Therapy group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy group (TG) received one-session cognitive behavior therapy (CBT).
Study: 17902000
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list group (WG) did not receive therapy during the study period.
Study: 2595039
Drug: Alfentanil (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (median dose 1.1 mg, range 0.5-2.6 mg)
Study: 2595039
Drug: Papaveretum (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum (median dose 10 mg, range 5-15 mg) and Diazepam (median dose 8 mg, range 0-20 mg)
Study: 1106038
Drug: Safapryn (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safapryn (3.6 g aspirin + 3.0 g paracetamol daily)
Study: 1106038
Drug: Phenylbutazone (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (3000 mg)
Study: 1106038
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg phenylbutazone daily
Study: 31625704
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (ACE inhibitors or ARBs)
Study: 28760590
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal ointment
Study: 28760590
Drug: Honey vaginal
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey vaginal ointment
Study: 21663857
Drug: Docetaxel 38
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 38 mg/m²
Study: 21663857
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m²
Study: 15830733
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine (1 mg/kg every 30 min) with oral alcohol (1 g/kg following the initial cocaine dose and a second drink at +60 min)
Study: 12855610
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of zoledronic acid (Zol)
Study: 12855610
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of zoledronic acid (Zol)
Study: 9856709
Drug: Fentanyl (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (3 microg/ml) alone
Study: 9856709
Drug: Fentanyl with
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl with 0.5 microg/ml epinephrine
Study: 9856709
Drug: Fentanyl with
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl with both 0.01% bupivacaine and 0.5 microg/ml epinephrine
Study: 382154
Drug: 1% domperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% domperidone drops (0.3 mg/kg t.d.s. before meals)
Study: 382154
Drug: 1% metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% metoclopramide drops (0.3 mg/kg t.d.s. before meals)
Study: 11383934
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (tPA) treatment with imaging exclusion criteria
Study: 26419527
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (tPA) treatment
Study: 31508533
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (Mg) during even-numbered chemotherapy courses (arm AB)
Study: 31508533
Drug: No magnesium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No magnesium supplementation during odd-numbered chemotherapy courses (arm BA)
Study: 31508533
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (Mg)
Study: 27443660
Drug: Pharmathen quetiapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmathen quetiapine 400 mg prolonged-release formulation
Study: 27443660
Drug: AstraZeneca Seroquel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AstraZeneca Seroquel Prolong® 400 mg prolonged-release formulation
Study: 22173140
Drug: Mass distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass distribution of a single dose of oral azithromycin for trachoma
Study: 21526662
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) with propofol 4 microg/ml and remifentanil 4 ng/ml
Study: 21526662
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled infusion (MCI) with conventional-dose-weight infusion method
Study: 21526662
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled infusion (MCI)
Study: 15836571
Drug: 3-mg subcutaneous
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-mg subcutaneous sumatriptan
Study: 15836571
Drug: 6-mg subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mg subcutaneous sumatriptan